Damae Medical, a company specializing in advanced skin imaging, has secured $17,417,062 in new funding. This significant investment will support the company's mission to revolutionize the screening, management, and follow-up of skin cancers such as melanoma and carcinoma. Damae Medical achieves this through its deepLiveā¢ solution, which offers an accurate, fast, and reliable optical examination without the need for an invasive biopsy.
The deepLiveā¢ medical device is CE marked and leverages proprietary LC-OCT (Line-field Confocal Optical Coherence Tomography) technology. This innovative system provides high-resolution 3D images of the skin's various layers at a cellular level, enhanced by integrated software and Artificial Intelligence modules. Protected by six patent families and featured in over 100 scientific publications, deepLiveā¢ is currently utilized in more than 50 referral centers across 10 countries. It is also adopted by leading cosmetic and pharmaceutical firms for research and evaluation purposes, transforming daily dermatological practice into a more efficient, reassuring, and non-invasive experience for patients.
Based in Paris and employing 30 individuals, Damae Medical has been recognized with multiple innovation awards, including from MIT Technology Review, Bpifrance, and the European Commission. The newly raised capital is earmarked to accelerate the expansion of deepLiveā¢'s market presence and to further advance its innovative imaging technology. This funding round builds on the company's substantial prior investment of over ā¬20 million since its inception in 2014. Looking ahead, Damae Medical plans to leverage this investment to drive sustained growth, enhancing its capabilities in early skin cancer detection and patient care globally.
